Premium
Mechanisms of anticancer action of HPMA copolymer‐bound doxorubicin
Author(s) -
Minko Tamara,
Kopečková Pavla,
Kopeček Jindřich
Publication year - 2001
Publication title -
macromolecular symposia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.257
H-Index - 76
eISSN - 1521-3900
pISSN - 1022-1360
DOI - 10.1002/1521-3900(200107)172:1<35::aid-masy35>3.0.co;2-n
Subject(s) - doxorubicin , internalization , intracellular , chemistry , cytosol , anticancer drug , mode of action , mechanism of action , programmed cell death , enzyme , microbiology and biotechnology , pharmacology , biophysics , drug , cell , biochemistry , apoptosis , biology , in vitro , chemotherapy , genetics
This paper summarizes the peculiarities of HPMA copolymer‐bound doxorubicin as an anticancer drug. It was found that polymer‐bound doxorubicin demonstrated higher anticancer activity compared with free doxorubicin. This phenomenon was explained by the following mechanisms of its anticancer action: preferential accumulation in tumors, internalization in membrane‐limited organelles, ability to overcome existing multidrug resistance and not to induce it de novo , high intracellular toxicity and inhibition of detoxification enzymes, cell death induction by the activation of specific signaling pathways, and triggering of caspase activation cascades.